Severe Skin Reaction Related to Concurrent Radiotherapy with Sunitinib in Renal Cell Carcinoma-A Case Report

腎細胞癌患者同時接受放射線治療與sunitinib導致之嚴重皮膚反應－病例報告

方本詞(Pen-Tzu Fang) ； 連熙隆(Shi-Long Lian) ； 吳文正(Wen-Jeng Wu) ； 吳青穎(Ching-Ying Wu) ； 蘇月秋(Yue-Chiu Su)

《放射治療與腫瘤學》 16卷2期 (2009/06) Pp. 151-156

https://doi.org/10.6316/TRO/200916(2)151

摘要

Sunitinib為一可抑制血小板生長因子(PDGF)及血管內皮生長因子(VEGF)的酩氨酸激釅抑制齊。它對於轉移及具細胞激素抗性之腎細胞癌有顯著的效力。此篇主要目的為探討其與放射線治療併用時的皮膚反應。病患在併用放射線治療與sunitinib時在照野內產生嚴重的皮膚反應。此情形在其他文獻中並未被提及過。我們假設照野內之皮膚反應是因sunitinib促使產生的。因此當RCC病患接受放射線治療時給予sunitinib時，進一步的觀察可能是必須的。

關鍵字

sunitinib ； 腎細胞癌 ； 放射線治療 ； 手足症候群

並列摘要

Sunitinib is a tyrosine kinase inhibitor of both platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) receptors. It has shown great efficacy in metastatic and cytokine refractory advanced renal cell carcinoma. The focus of this article is on its dermatological effect in combination with radiotherapy. In this case report, the patient concurrently received sunitinib and radiotherapy developed severe skin reaction in irradiation field. This type of skin reaction has never been reported in the literature. We hypothesized that the skin reaction in radiation field may be precipitated by sunitinib. Further observation may be warranted while sunitinib is prescribed to RCC patients receiving radiotherapy.

並列關鍵字

Sunitinib ； Renal cell carcinoma ； Radiotherapy ； Hand foot syndrome